Filing Flows › Heron Therapeutics (HRTX) › ZYNRELEF revenue
Heron Therapeutics (HRTX) ZYNRELEF revenue by quarter
Heron Therapeutics' ZYNRELEF revenue was $11.1M in Q2 2026 (second quarter 2026), +8% from Q1 2026. Over the last 7 quarters it ranged from $8.0M (Q1 2025) to $12.5M (Q4 2025).
| Quarter | ZYNRELEF revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $11.1M | +8% | +35% |
| Q1 2026 | $10.2M | -18% | +27% |
| Q4 2025 | $12.5M | +35% | +48% |
| Q3 2025 | $9.3M | +14% | — |
| Q2 2025 | $8.2M | +2% | — |
| Q1 2025 | $8.0M | -5% | — |
| Q4 2024 | $8.5M | — | — |
Q2 2026 at a glance
Heron Therapeutics, Q2 2026: revenue $37.7M (+1% year over year), operating margin -5.4%, net loss $5.5M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Heron Therapeutics' ZYNRELEF revenue?
Heron Therapeutics' ZYNRELEF revenue was $11.1M in Q2 2026 (second quarter 2026), +8% from Q1 2026.
How has Heron Therapeutics' ZYNRELEF revenue changed?
Over the last 7 quarters it ranged from $8.0M (Q1 2025) to $12.5M (Q4 2025).